BioNTech SE logo

BioNTech SENASDAQ: BNTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Germany

IPO:

10 October 2019

Next earnings report:

04 November 2024

Last dividends:

02 June 2022

Next dividends:

N/A
$26.95 B
-69%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
46%vs. sector
-8%vs. 3y high
73%vs. sector

Price

pre-market | 19 min ago
$113.34-$0.60(-0.53%)
$138.58 M$659.83 M
$138.58 M-$869.80 M

Analysts recommendations

Institutional Ownership

BNTX Latest News

BioNTech to Host Innovation Series R&D Day on November 14, 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.

BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
zacks.com25 October 2024 Sentiment: POSITIVE

On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.

BioNTech's Oncology Gamble: High Stakes, Big Potential
seekingalpha.com21 October 2024 Sentiment: POSITIVE

BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and treatments remain unaffected, signaling potential for resolution.

BioNTech (BNTX) Presents at Innovation Series: AI Day
seekingalpha.com03 October 2024 Sentiment: POSITIVE

BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan Richardson - Chief Strategy Officer, BioNTech Nacef Labidi - Head of Infrastructure, InstaDeep Alex Laterre - Head of Research, InstaDeep Alex Graves - Research Scientist, InstaDeep Bora Guloglu - Research Scientist, InstaDeep Julia Gimbernat - Product Manager, InstaDeep Arnu Pretorius - Research Scientist, InstaDeep Youssef Ben Dhieb - Senior ML Engineer, InstaDeep Thomas Pierrot - Research Scientist, InstaDeep Maren Lang - Senior Director, Bioinformatics R&D, BioNTech Marie Lopez - Research Engineer Team Lead, InstaDeep Daniel Rothenberg - Associate Director, Proteomics, BioNTech Michael Rooney - Director, Computational Biology, BioNTech Nicolas Lopez Carranza - Head of BioAI, InstaDeep Hippolyte Jacomet - Research Engineer, InstaDeep Sven Coutandin - Director, Global R&D Automation, BioNTech David Drakard - Senior Research Engineer, InstaDeep Michael Dahms - Director, Digitization R&D Labs, BioNTech Conference Call Participants Sam Fazeli - Bloomberg Intelligence Harry - Time Magazine Ian Johnston - Financial Times Unidentified Speaker - Karim Beguir Hi everyone. Welcome to AI Day.

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
globenewswire.com01 October 2024 Sentiment: POSITIVE

LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary  InstaDeep Ltd . (“InstaDeep”), today presents an overview of its AI approach during an edition of the Company's Innovation Series, AI Day.

BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.
barrons.com19 September 2024 Sentiment: POSITIVE

Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.

Trade It or Fade It: The week's big biotech moves
youtube.com13 September 2024 Sentiment: NEUTRAL

Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.

BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
seekingalpha.com11 September 2024 Sentiment: POSITIVE

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.

BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials Initiated
globenewswire.com25 August 2024 Sentiment: POSITIVE

Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research

Lung cancer patient is first in UK to receive experimental vaccine
news.sky.com22 August 2024 Sentiment: POSITIVE

A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.

What type of business is BioNTech SE?

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

What sector is BioNTech SE in?

BioNTech SE is in the Healthcare sector

What industry is BioNTech SE in?

BioNTech SE is in the Biotechnology industry

What country is BioNTech SE from?

BioNTech SE is headquartered in Germany

When did BioNTech SE go public?

BioNTech SE initial public offering (IPO) was on 10 October 2019

What is BioNTech SE website?

https://www.biontech.de

Is BioNTech SE in the S&P 500?

No, BioNTech SE is not included in the S&P 500 index

Is BioNTech SE in the NASDAQ 100?

No, BioNTech SE is not included in the NASDAQ 100 index

Is BioNTech SE in the Dow Jones?

No, BioNTech SE is not included in the Dow Jones index

When was BioNTech SE the previous earnings report?

No data

When does BioNTech SE earnings report?

The next expected earnings date for BioNTech SE is 04 November 2024